Elutia Inc Class A (ELUT)

Elutia closed the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million in October 2025. Elutia reported its third-quarter 2025 financial results, which included the closing of the BioEnvelope business sale. Elutia reported preliminary net sales of approximately $3.3 million for Q4 2025, a 16% increase compared to Q4 2024 (excluding the divested BioEnvelope business). The share price experienced a significant decline over the past year, dropping from $3.45 per share on January 3, 2025, to $0.64 per share as of January 2, 2026. Some analysts have a "Strong Buy" rating with a 12-month price target of $7.00. Elutia appointed Guido J. Neels to its Board of Directors in October 2025.

Limited data suggests a seasonal strength for Elutia's stock between December 7 and February 27. Demand for Elutia's products is likely driven by ongoing medical needs and surgical schedules rather than strong seasonal fluctuations. The expansion of EluPro indicates a steady effort to increase market penetration.

Elutia, Inc. is a regenerative medicine company focused on developing and commercializing drug-eluting biologics products to improve surgical outcomes, particularly for patients receiving implantable medical devices. The company operates in the Healthcare sector, specifically in the Medical Devices and Instruments industry. Elutia's business is segmented into Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment historically generating the maximum revenue. Key products include EluPro BioEnvelope, CanGaroo BioEnvelope, SimpliDerm, ProxiCor, Tyke, VasCure, and NXT-41x.

Elutia, Inc. primarily develops and commercializes its products in the United States, serving hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors.

Elutia's brand reputation has been shaped by its strategic refocus and product developments, including an Edison Award for innovation in post-surgical recovery. The successful launch and growth of its EluPro product line and the partnership with Boston Scientific have contributed positively. The company's pivot towards the NXT-41x platform for breast reconstruction is also a key aspect. Challenges include a significant stock price decline and litigation from a historical product recall.

Institutional investors own 74.03% of Elutia's stock, while insiders own 27.60%. Major institutional owners include Nantahala Capital Management, LLC, AIGH Capital Management LLC, and Silverarc Capital Management, Llc. Major individual owners (insiders) include Highcape Capital LP, Highcape Capital LLC, and Kevin Rakin. Insiders have bought more company stock than they have sold in the past three months.